Market news

If approved, Joenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or moreDecision follows recent approval of Joenja for children aged 4 to 11 years with APDS weighing at least 27 kgPDUFA target action date of January 30, 2027 Leiden, the Netherlands, September 25, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration

Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation Separately, Pharming expects to report topline results from a Phase II trial of leniolisib in CVID in Q4 2026 Leiden, the Netherlands, September 22, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that a late-breaking abstract highlighti

Pharming Group N.V. (NASDAQ:PHAR) announced on September 11 that the U.S. Food and Drug Administration approved Joenja for children aged 4–11 with activated PI3K delta syndrome, or APDS, who weigh at least 27 kilograms. APDS disrupts immune function. The new 40 mg and 50 mg tablet strengths expand dosing options for Joenja, or leniolisib. The […]

FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kgNewly approved Joenja doses are expected to be available in October Leiden, the Netherlands, September 11, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental

Detailed price information for Tenax Therapeutics (TENX-Q) from The Globe and Mail including charting and trades.

Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwide OrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and distribution in Japan Leiden, the Netherlands, August 13, 2026: Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced the commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with activated PI3K delta syndrome (APDS) aged 4 years and older, following it

Detailed price information for Pharming Group N.V. ADR (PHAR-Q) from The Globe and Mail including charting and trades.

Leiden, the Netherlands, August 4, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12-13, 2026. Michael Levitan, VP Investor Relations and Capital Markets, will participate in a Fireside Chat Q&A session on Wednesday, August 12 at 10:00 EDT/16:00 CEST. For more information about the conference, or to schedule a one-on-one meeting with Pharming’s management team, please

Pharming Group guidance cut and half year results draw investor focus Pharming Group (ENXTAM:PHARM) has drawn fresh attention after lowering its 2026 revenue guidance by US$30 million and reporting half year 2026 results that showed reduced sales but a smaller net loss. See our latest analysis for Pharming Group. Pharming Group’s guidance cut and half year 2026 results appear to have fed into weaker sentiment, with the stock’s share price down 26.76% over 30 days and a 1 year total...

Detailed price information for Pharming Group NV Ord (PHGUF) from The Globe and Mail including charting and trades.

Motley Fool Press Release.

Pharming Group (PHAR) reported a Q2 earnings Thursday of $0.002 per diluted share, compared with $0.

Pharming Group (NASDAQ:PHAR) reported second-quarter revenue of $90.2 million, down 3% from a year earlier, as growth from its Joenja treatment partly offset lower sales of hereditary angioedema therapy RUCONEST. The company reduced its full-year revenue outlook by $30 million but said it expects RU

Pharming Group (PHGUF) navigates a mixed quarter with strong Joenja growth and cost discipline, offset by Ruconest revenue declines and a lowered full-year outlook.

For investor audiences and media only Second quarter 2026 total revenues decreased by 3% to US$90.2 million, compared to the second quarter 2025RUCONEST® revenue was US$72.3 million, a 10% decrease compared to the second quarter 2025 and a 24% increase compared to the first quarter 2026, with active patient base 93% of year-ago and strong new patient enrollmentsJoenja® revenue was US$17.9 million, a 40% increase compared to the second quarter 2025, reflecting continued strong U.S. and internatio

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Leiden, the Netherlands, July 16, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the second quarter and first half 2026 and provide a business update on Thursday, July 30, 2026. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CEST/07:30 am EDT. To participate in the conference call or to watch the live webcast, please register in a